Immunovant, Inc.
IMVT
Rank in Stocks
#3099
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Share Price
$28.44
Market Cap
$5.87B
Change (1 day)
-0.52%
Change (1 year)
47.89%
Country
US
Trade Immunovant, Inc. (IMVT)
Category
Healthcare
Stock split history for Immunovant, Inc. (IMVT)
Immunovant, Inc. stock (symbol: IMVT) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 21, 2026.
One IMVT share bought prior to Oct 21, 2026 would equal to 0 IMVT shares today.
The most recent stock split occurred on Oct 21, 2026.
One IMVT share bought prior to Oct 21, 2026 would equal to 0 IMVT shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
